- Home
- FLYX vs STTK Comparison
FLYX vs STTK Comparison
Compare FLYX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYX
- STTK
- Stock Information
- Founded
- FLYX 2015
- STTK 2016
- Country
- FLYX United States
- STTK United States
- Employees
- FLYX N/A
- STTK N/A
- Industry
- FLYX Blank Checks
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- FLYX Finance
- STTK Health Care
- Exchange
- FLYX Nasdaq
- STTK Nasdaq
- Market Cap
- FLYX 39.4M
- STTK 38.4M
- IPO Year
- FLYX N/A
- STTK 2020
- Fundamental
- Price
- FLYX $2.39
- STTK $0.76
- Analyst Decision
- FLYX
- STTK Hold
- Analyst Count
- FLYX 0
- STTK 4
- Target Price
- FLYX N/A
- STTK $3.00
- AVG Volume (30 Days)
- FLYX 13.5K
- STTK 211.2K
- Earning Date
- FLYX 08-13-2025
- STTK 08-12-2025
- Dividend Yield
- FLYX N/A
- STTK N/A
- EPS Growth
- FLYX N/A
- STTK N/A
- EPS
- FLYX N/A
- STTK N/A
- Revenue
- FLYX $335,427,000.00
- STTK $4,606,000.00
- Revenue This Year
- FLYX $28.47
- STTK N/A
- Revenue Next Year
- FLYX $22.44
- STTK N/A
- P/E Ratio
- FLYX N/A
- STTK N/A
- Revenue Growth
- FLYX 5.38
- STTK 69.65
- 52 Week Low
- FLYX $1.79
- STTK $0.69
- 52 Week High
- FLYX $4.90
- STTK $4.26
- Technical
- Relative Strength Index (RSI)
- FLYX 47.90
- STTK 41.22
- Support Level
- FLYX $2.01
- STTK $0.73
- Resistance Level
- FLYX $2.59
- STTK $0.92
- Average True Range (ATR)
- FLYX 0.24
- STTK 0.07
- MACD
- FLYX 0.00
- STTK 0.01
- Stochastic Oscillator
- FLYX 55.16
- STTK 16.81
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.